---
title: Evaluation of a training set
---

Before performing large-scale virtual screening, it is essential to validate the docking workflow using a **well-characterized benchmark set**.  
This allows verifying that the selected docking parameters, scoring functions, and receptor models can **reproduce experimental trends** and correctly discriminate between active and less active compounds.

To date, no **triazole-based inhibitors bearing a vinylsulfone warhead** have been reported, except for one analog described by *Brak et al.* (2008).  
In their pioneering work and follow-up publications, the same group explored triazole-containing analogues with alternative reactive moieties, mainly **4-fluorophenoxymethyl ketones (4FPMKs)**, originally developed for **cathepsin** inhibition.

Their design strategy consisted in **replacing the scissile amide bond** of peptidic inhibitors with a **1,4-disubstituted 1,2,3-triazole** ring while systematically varying the **R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup>** substituents to explore ligand‚Äìtarget complementarity. Subsequent optimization led to a family of **20 triazole-based 4FPMK derivatives**, collectively showing a wide **inhibitory range against Cruzipain (CZP)**, from **3 nM to 23 ¬µM**.  Although their **SAR remains only partially explored**, these analogues demonstrated good trypanocidal activity, acceptable physicochemical profiles, and promising *in vivo* efficacy - despite safety concerns linked to CYP3A4 inhibition. One representative compound, **Ts-370**, was co-crystallized with CZP (PDB ID: **3IUT**), providing valuable structural insights into the binding mode of this series and serving as a solid reference for further *in silico* modeling efforts. 

For the purpose of this workshop, we will use this small but well-defined set as a **test set**. The goal is to evaluate whether our SBDD workflow can reproduce the **binding trends and relative affinities** observed experimentally, using the available crystallographic and biochemical data.

While best practice in computational drug design recommends **larger and chemically diverse training/test sets**, this reduced dataset provides a **realistic and time-efficient framework** for validating the docking setup and analyzing performance under controlled conditions during this workshop.

#### Test set

---
<figure>
  <p align="center">
  <img src="/TidyScreen_v2_docs_new/img/Training_Set_Workshop.png" alt="Description of image" width="700"/>
  <figcaption>  Chemical structures of the compounds considered as the <b>test set</b>. The reference inhibitor <b>K777</b>, its triazolized analogue (<b>Tz-K777</b>), and the unique triazole-based vinylsulfone derivative reported to date (<b>KB-38</b>), along with the series of 20 <b>4FPMK</b> derivatives originally synthesized by Jonathan A. Ellman (check Table below), are included. </figcaption>
  </p>
</figure>
---


| **ID** | **R<sup>1</sup>** | **R<sup>2</sup>** | **X** | **R<sup>3</sup>** | **IC50 (nM)** |
|:-------:|:-------|:-------|:------|:-------|:--------------:|
| **K777** | - | - | - | - | **2** |
| **Tz-K777** | - | - | - | - | **n.d.** |
| **KB-38** | - | - | - | - | **n.d.** |
| **Ts-3** | *n*-Bu | *c*-Pent | CH‚ÇÇ | PzPm | **3** |
| **Ts-5** | *n*-Bu | *c*-Pent | CH‚ÇÇ | BnThia | **5** |
| **Ts-25** | msp | *c*-Pent | CH‚ÇÇ | BnThia | **25** |
| **Ts-27** | *n*-Bu | *c*-Pent | CH‚ÇÇ | Quin | **27** |
| **Ts-37** | *n*-Bu | *i*-Pr | CH‚ÇÇ | BnThia | **37** |
| **Ts-63** | mop | *i*-Pr | CH‚ÇÇ | BnThia | **63** |
| **Ts-75** | *n*-Bu | *i*-Pr | CH‚ÇÇ | PzPm | **75** |
| **Ts-124** | mop | *c*-Pent | CH‚ÇÇ | BnThia | **124** |
| **Ts-125** | msp | *i*-Pr | CH‚ÇÇ | BnThia | **125** |
| **Ts-340** | mop | *i*-Pr | CH‚ÇÇ | Quin | **340** |
| **Ts-370** | *n*-Bu | *i*-Pr | CH‚ÇÇ | Quin | **370** |
| **Ts-467** | msp | *i*-Pr | CH‚ÇÇ | PzPm | **467** |
| **Ts-560** | msp | *i*-Pr | CH‚ÇÇ | Quin | **560** |
| **Ts-790** | msp | *c*-Pent | CH‚ÇÇ | BnFur | **790** |
| **Ts-880** | msp | *i*-Pr | CH‚ÇÇ | BnFur | **880** |
| **Ts-1100** | *n*-Bu | *i*-Pr | CH‚ÇÇ | Py | **1100** |
| **Ts-1350** | *n*-Bu | *i*-Pr | C=O | Quin | **1350** |
| **Ts-2820** | mop | *c*-Pent | CH‚ÇÇ | PzPm | **2820** |
| **Ts-3590** | *n*-Bu | *i*-Pr | C=O | BnThia | **3590** |
| **Ts-23000** | *n*-Bu | *i*-Pr | C=O | Py | **23000** |

> **Note:** IC50 values correspond to inhibition of *Cruzipain* (CZP) and are expressed in nanomolar (nM). Compound IDs reflect their approximate potency order.


To streamline this stage, we provide a precompiled CSV file containing the **SMILES**, **compound IDs**, and **inhibitory potency labels** for all molecules included in the test set.

This file can be directly imported into your local **TidyScreen** project and integrated into the **chemspace database** (`chemspace.db`) for subsequent docking validation.

---

<details>
<summary>üìÇ <b>Download: TS_Workshop.csv</b></summary>

[‚û°Ô∏è Click here to download the file](/files/TS_Workshop.csv)

</details>

After downloading, simply run the following command inside your Python environment to import the dataset into the chemspace module of your project:

```python title="workshop.py"
# Please check if the chemspace object is active! --> la_workshop_cs = chemspace.ChemSpace(la_workshop)
la_workshop_cs.input_csv("/PATH/TO/TS_Workshop.csv")
```

All entries will be automatically stored in your `chemspace.db` file under `/chemspace/processed_data/`, ready for use in the validation stage.

Now that the training/test dataset has been imported into your project, we will run a controlled **docking validation**  to ensure that the parameters previously optimized for CZP (and later to be used in large-scale screening) can reproduce reliable and consistent binding trends for known inhibitors.

So that, prepare all ligands in the `TS_Workshop` table, and convert them into docking-compatible formats.

```python title="workshop.py"
la_workshop_cs.generate_mols_in_table("TS_Workshop")
```

Instantiate a MolDock object to activate all docking-related functions within your current project, and set up the docking campaign using the previously validated CZP receptor model (ID = 3) and the optimized docking parameters (ID = 2).

```python title="workshop.py"
la_workshop_moldock = md.MolDock(la_workshop)

la_workshop_moldock.dock_table("TS_Workshop",
                               id_receptor_model=3,
                               id_docking_params=2)
```

Once the docking assay is created, TidyScreen automatically generates an execution script.

To execute the job, you may run from your terminal:

```bash
./docking_execution_1.sh
```

:::warning[Important]
Docking execution requires access to a local GPU board or a compatible GPU computing environment. If no GPU resources are available, these scripts cannot be executed, and docking should instead be run on a properly configured workstation or HPC cluster.
:::

###### Analysis

###### hCatL